Deadline: Pfizer - Research in Ulcerative Colitis
This competitive program seeks to support global research that helps to address Ulcerative Colitis data gaps and advances the understanding of etrasimod and / or tofacitinib role in the treatment landscape.
Potential applicants are encouraged to identify and address the data gaps and advances understanding the role of etrasimod and tofacitinib in UC treatment landscape. This may include
- Exploration for optimal ultrasonographic markers
- Evaluation of UC extraintestinal manifestations
- Evaluation in specific subgroups of special interest
- Evaluation of advanced therapy sequencing strategy
Funding Range and Project Length: Individual projects requesting up to USD 200,000 will be considered. The project length will be a maximum of eighteen (18) months.
Contact Details
Internal: ird@dal.ca
External: Amanda Stein (amanda.j.stein@pfizer.com) with the subject line 鈥淩esearch in Ulcerative Colitis (UC) 2024.鈥�
Deadlines
Internal: July 22, 2024
External: August 5, 2024
The grants facilitator for your faculty can be found on the staff contact page. For additional resources, click here for guidance on internal deadlines and submission processes.
Time
Additional Dates/Times